Scientific Program 

Wednesday, September 11, 2024

12:00-13:00 Pre-Congress Industry Symposium Hall A

 

11:30-13:00 Pre-Congress Symposium:
AI in breast imaging
Hall B
Chairpersons
11:30-11:45 Hype or hope: Breast imaging and Artificial Intelligence
Gerald Lip,
Aberdeen, Scotland, UK
11:45-12:00 AI in breast imaging
Karla Sepulveda,
Houston, TX, USA
12:00-13:00 Round Table Discussion:
James Blackwood, Glenboig, Scotland, UK
Julia Camps Herrero, Valencia, Spain

 

13:00-13:15 Congress Opening Hall A
Chairpersons Leena Chagla, Cheshire, UK
Bruce Mann, Melbourne, Australia
Welcome from Congress chairpersons

 

13:15-14:45 Session 1: Neoadjuvant therapy Hall A
Chairpersons Leena Chagla, Cheshire, UK
Bruce Mann, Melbourne, Australia
13:15-13:50
13:15
13:25
13:35
Debate: That cT1cN0 HER2+ve should have NAST
Yes: Javier Cortes, Madrid, Spain
No: Sarah Downey, Norfolk, UK 
Discussion
13:50-14:05 Imaging during NAST
Julia Camps Herrero, Valencia, Spain
14:05-14:45
14:05
14:15
14:25
Debate: Patients with a positive TAD post NACT should have completion axillary clearance  
Yes: Stephen Grobmyer, Abu Dhabi, UAE
No: Amit Goyal, Derby, UK
Discussion

 

14:40-15:10 Coffee break, poster viewing and exhibition visit

 

15:10-16:10 Session 2: Imaging Hall A
Chairpersons Nisha Sharma, Leeds, UK
Karla Sepulveda, Houston, TX, USA
15:10-15:40
15:10
15:20
15:30
Debate: The Contrast Breast Imaging should be routine prior to surgery for DCIS or invasive cancer 
Yes: Bruce Mann, Melbourne, Australia
No: Stuart McIntosh, Belfast, UK 
Discussion
15:40-16:10
15:40
15:50
16:00
Debate: The CEM should be the surveillance imaging test for most patient with past history of breast cancer 
Yes: Allison Rose, Melbourne, Australia
No: Sarah Savaridas, Dundee, Scotland, UK
Discussion

 

15:10-16:10 Session 3: HER2+ve disease Hall B
Chairpersons Richard de Boer, Melbourne, Australia
Olga Oikonomidou, Edinburgh, Scotland, UK
15:10-15:40
15:10
15:20
15:30
Debate: Do anthracyclines still have a place in the treatment of early stage HER2+ve BC?
Yes: Richard Simcock, Surrey, UK
No: Kevin Kalinsky, Atlanta, GA, USA
Discussion
15:40-15:55 HER2 low
Sarah Pinder, London, UK
15:55-16:10 Is there a threshold for systemic treatment of HER2+ve cancer?
Iain MacPherson, Glasgow, Scotland, UK

 

16:10-17:10 Session 4: DCIS Hall A
Chairpersons Bruce Mann, Melbourne, Australia
Tracey Irvine,
Surrey, UK 
16:10-16:40
16:10
16:20
16:30
Debate: That most patients with DCIS should have radiotherapy after Breast Conserving Surgery
Yes: Frank A. Vicini, Farmington Hillis, MI, USA
No: Elinor Sawyer, London, UK
Discussion
16:40-17:10
16:40
16:50
17:00
Debate: That active surveillance for low risk DCIS is a reasonable option
Yes: Shelley Potter, Bristol, UK
No: Henry J. Cain, Newcastle upon Tyne, UK
Discussion

 

 16:10-17:10 Session 5: Metastatic HR+ve breast cancer
Hall B
Chairpersons Richard de Boer, Melbourne, Australia
Olga Oikonomidou, Edinburgh, Scotland, UK
16:10-16:40 What to do after progression on CDKi
Kevin Kalinsky, Atlanta, GA, USA
16:40-17:10
16:40
16:50
17:00
Debate: That CDKi should be first line treatment for ~all HR+ve MBC 
Yes: David Cameron, Edinburgh, Scotland, UK
No: Mark Verrill, Newcastle upon Tyne, UK
Discussion

 

17:15-18:15 Networking Reception

 

Thursday, September 12, 2024

 07:00-08:30 Industry Breakfast Symposium Hall A

 

07:00-08:30 Industry Breakfast Symposium Hall B

 

 08:30-09:30 Session 6: Breast cancer in young women Hall A
Chairpersons Ramsey Cutress, Southampton, UK
Yazan Masannat,
 Essex, UK
08:30-09:00 Controversies in breast cancer management in young women
Ann Partridge, Boston, MA, USA
09:00-09:30
09:00
09:10
09:20
Debate: That women <35 with breast cancer should be advised to have bilateral total mastectomy
Yes: Michael Alvarado, San Francisco, CA, USA
No: J. Michael Dixon, Edinburgh, Scotland, UK
Discussion

 

09:30-11:00 Session 7: Screening Hall A
Chairpersons Sarah Downey, Norfolk, UK
Laszlo Romics, Glasgow, Scotland, UK
09:30-10:00
09:30
09:40
09:50
Debate: That a change to risk-adjusted screening is urgent and feasible
Yes: D. Gareth Evans, Manchester, UK
No: Cliona Kirwan, Manchester, UK
Discussion
10:00-10:25 CBI in screening
Allison Rose, Melbourne, Australia
10:25-11:00
10:25
10:35
10:45
Debate: That women at low risk for breast cancer should only be screened every 5 years
Yes: Nisha Sharma, Leeds, UK
No: TBA
Discussion

 

09:30-11:00 Session 8: Triple negative breast cancer Hall B
Chairpersons Richard de Boer, Melbourne, Australia
Richard Simcock, Surrey, UK
09:30-10:00
09:30
09:45
10:00
Debate: That all stage 2/3 TNBC patients should be treated according to Keynote522 regimen
Yes: Olga Oikonomidou, Edinburgh, Scotland, UK
No: Carlo Palmieri, Liverpool, UK
Discussion
10:10-10:25 TNBC subtypes: Do they have clinical significance?
Matthew J. Ellis, Houston, TX, USA
10:25-11:00
10:25
10:35
10:45
Debate: Asymptomatic patients with high-risk TNBC should undergo surveillance imaging
Yes: Ann Partridge, Boston, MA, USA
No: Alistair Ring, London, UK
Discussion

 

11:00-11:30 Coffee break, poster viewing and exhibition visit

 

11:30-12:30 Session 9: Metastatic Breast Cancer Hall A
Chairpersons Olga Oikonomidou, Edinburgh, Scotland, UK
Iain MacPherson, Glasgow, Scotland, UK
11:30-12:00
11:30
11:40
11:50
Debate: That molecular testing of tumours should be routine for patients with metastatic breast cancer 
Yes: Marina Parton, London, UK
No: Richard de Boer, Melbourne, Australia
Discussion
12:00-12:30
12:00
12:10
12:20
Debate: SABR should be considered in most patients with oligometastatic breast cancer    
Yes: John Conibear, London, UK
No: Stephen Harrow, Edinburgh, Scotland, UK
Discussion

 

11:30-12:30 Session 10: Free Papers Hall B
Chairpersons Lynda Wyld, Sheffield, UK
Raghavan Vidya, Birmingham, UK
11:30-11:40
11:40-11:50
11:50-12:00
12:00-12:10
12:10-12:20
12:20-12:30

 

 12:30-13:30 Pre-Lunch Industry Symposium Hall A

 

12:30-13:30 Pre-Lunch Industry Symposium Hall B

 

13:30-14:30 Lunch break, poster viewing and exhibition visit

 

14:30-15:30 Session 11: Genetics Hall A
Chairpersons Alastair Thompson, Houston, TX, USA
Douglas Ferguson,
Exeter, UK
14:30-15:00
14:30
14:40
14:50
Debate: That most cancer patients with gene mutations should be offered breast conservation  
Yes: D. Gareth Evans, Manchester, UK
No: Stuart McIntosh, Belfast, UK 
Discussion
15:00-15:15  The ‘new genes’: What do they mean for patients and families?
Arran K. Turnbull, Edinburgh, Scotland, UK
15:15-15:30  What is the appropriate timing of risk reduction BSO in BRCA patients?
Cameron Martin, Edinburgh, Scotland, UK

 

14:30-15:30 Session 12: Free Papers Hall B
Chairpersons
14:30-14:40
14:40-14:50
14:50-15:00
15:00-15:10
15:10-15:20
15:20-15:30

 

15:30-16:00 Coffee break, poster viewing and exhibition visit

 

16:00-17:30 Session 13: Adjuvant endocrine therapy Hall A
Chairpersons Cliona Kirwan, Manchester, UK
John Benson,
Cambridge, UK
16:00-16:45 Why my assay is best
16:00 PAM 50
Matthew J. Ellis, Houston, TX, USA
16:15 ODX
Kevin Kalinsky, Atlanta, GA, USA
16:30
Mammaprint
William Audeh, Los Angeles, CA, USA
16:45-17:30
16:45
17:00
17:15
Debate: That adjuvant CDKs should be recommended for intermediate risk ER+HER2-EBC
Yes: Kevin Kalinsky, Atlanta, GA, USA
No: Alistair Ring, London, UK
Discussion

 

Friday, September 13, 2024

 07:00-08:30 Industry Breakfast Symposium Hall A

 

07:00-08:30 Industry Breakfast Symposium Hall B

 

08:30-10:00 Session 14: Reconstruction Hall A
Chairpersons Leena Chagla, Cheshire, UK
Krishna Clough, Paris, France
08:30-09:00 Fat grafting, realistic expectations and long-term results
Krishna Clough, Paris, France
09:00-10:00 MDT Round Table Discussion on tricky oncoplastic/reconstructive topics
Case presenters:
Rajiv Dave, Manchester, UK 
Kenneth Elder, Edinburgh, Scotland, UKPanel:
J. Michael Dixon, Edinburgh, Scotland, UK
Douglas Ferguson, Exeter, UK
Adam Gilmour, Glasgow, Scotland, UK
Andrew Malyon, Glasgow, Scotland, UK
James Mansell, Glasgow, Scotland, UK
Lynda Wyld, Sheffield, UK

 

08:30-10:00 Session 15: Supportive care Hall B
Chairpersons Olga Oikonomidou, Edinburgh, Scotland, UK
Katy Ellis, Manchester, UK
08:30-09:00 TBA
Lesley Fallowfield, Sussex, UK
09:00-09:30 Post-menopausal symptoms symptoms and how to manage them
Paula Briggs, Liverpool, UK
09:30-10:00 TBA
Marina Parton, London, UK

 

10:00-10:30 Coffee break, poster viewing and exhibition visit

 

10:30-11:30 Session 16: Locoregional management Hall A
Chairpersons Krishna Clough, Paris, France
Stephen Grobmyer,
Abu Dhabi, UAE
10:30-11:00
10:30
10:40
10:50
Debate: That patients with heavy axillary nodal disease pre-NACT should have axillary dissection irrespective of response to NACT
Yes: Alastair Thompson, Houston, TX, USA
No: Leena Chagla, Cheshire, UK
Discussion
11:00-11:30
11:00
11:10
11:20
Debate: That all patients with 1-3 macrometastases in axillary nodes should have Regional Nodal Radiation  
Yes: Elinor Sawyer, London, UK 
No: Michael Douek, London, UK
Discussion

 

11:30-12:30 Session 17: Breast Cancer 2035 Hall A
Chairpersons Leena Chagla,Cheshire, UK
Bruce Mann,
Melbourne, Australia
11:30-11:45 Oncoplastic surgery in 2035
Krishna Clough, Paris, France
11:45-12:00 Early detection in 2035
Karla Sepulveda, Houston, TX, USA
12:00-12:15 Management of Stage 1 breast cancer in 2035
Bruce Mann, Melbourne, Australia
12:15-12:30 Systemic therapy in 2035
Olga Oikonomidou, Edinburgh, Scotland, UK

 

 12:30-12:45 Congress closing and Award presentation Hall A
Chairpersons Leena Chagla, Cheshire, UK
Bruce Mann, Melbourne, Australia
  • Program is subject to change
Skip to content